Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Taysha Gene Therapies, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Form of Pre-Funded Warrant to Purchase Common Stock",
"Form of Securities Purchase Agreement, by and among Taysha Gene Therapies, Inc. and the Purchasers",
"Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results",
"Taysha Gene Therapies Announces $150 Million Private Placement Financing"
05/15/2023 8-K Quarterly results
Docs: "Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update"
11/08/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update"
08/11/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update"
05/16/2022 8-K Quarterly results
03/31/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
05/11/2021 8-K Quarterly results
Docs: "Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update"
03/05/2021 8-K/A Quarterly results
Docs: "Taysha Gene Therapies Reports Third Quarter 2020 Financial Results and Provides Business Update"
11/12/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 12, 2020 Taysha Gene Therapies, Inc. Delaware 001-39536 84-3199512 2280 Inwood Road Dallas, Texas 75235 612-0000 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 unde...",
"Taysha Gene Therapies Reports Third Quarter 2020 Financial Results and Provides Business Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy